NANO TARGETING & THERAPY BIOPHARMA INC.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
NTT Biopharma's product pipeline centers on its MSN platform, featuring NTT‑001 for primary and metastatic brain cancer, NTT‑002 for highly metastatic colorectal cancer, and a series of eye-drop nanoformulations (NTT‑003 and NTT‑004) for retinal diseases
Founded Year
2016
Unified Business No.
52374205
Status
Active
Number of Employees
0
Total Paid-in
Capital
93,849,448 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Nano Targeting and Therapy (NTT) Biopharma Inc. is a cutting-edge biotechnology company pioneering the use of mesoporous silica nanoparticles (MSNs) for the precise and efficient delivery of therapeutic molecules. Our vision is to tackle critical challenges and deliver improved solutions in drug delivery to address unmet medical needs in the fields of brain diseases, ocular and retinal diseases, oncology, and gene therapy. We are committed to create a new generation of effective nanomedicines that optimize therapies across a broad range of diseases.
